

EU FEMED 1st DISCUSSION FORUM

PROGRAMME

**The New FIH EMA Guideline:
Disruptive or Constructive?**

Jan de Hoon, PhD, MD, MSc
Center for Clinical Pharmacology
Leuven, Belgium

19 September 2018
KU LEUVEN, BELGIUM

The New FIH EMA Guideline: Disruptive or Constructive?

FACULTY MEMBERS

Dr. Sonja Beken	FAGG-AFMPS Brussels, Belgium
Prof. Dr. Jan de Hoon	University Leuven, Belgium
Dr. Izaak den Haas	QPS, Groningen, Netherlands
Dr. Yves Donazzolo	Eurofins Optimed, Grenoble, France
Dr. Tim Hardman	Niche Science & Technology, Richmond, UK
Dr. Sarah Heil	BfArM Bonn, Germany
Dr. Mario Iovino	Boehringer Ingelheim, Germany
Dr. Marc Martin	ANSM Paris, France
MUDr. Ondřej Palán	SUKL Prague, Czech Republic
Dr. Stefano Ponzano	EMA
Prof. Dr. Sylvie Rottey	University Gent, Belgium
Prof. Dr. Hildegard Sourgens	Consultant, München
Prof. Dr. Joop van Gerven	CCMO, Den Haag, Netherlands
Dr. Kirsty Wydenbach	MHRA, London, UK

The New FIH EMA Guideline: Disruptive or Constructive?

Forum = Experiment

Audience Interaction Made Easy

Live Q&A, Polls and Slide-sharing
for Events

slido




The New FIH EMA Guideline: Disruptive or Constructive?



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

20 July 2017
EMA/CHMP/SWP/28367/07 Rev. 1
Committee for Medicinal Products for Human Use (CHMP)



Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products

The New FIH EMA Guideline: Disruptive or Constructive?

